Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial
- PMID: 19461031
- DOI: 10.1161/STROKEAHA.108.546135
Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial
Abstract
Background and purpose: The relative contributions of on-treatment low- and high-density lipoprotein cholesterol (LDL-C, HDL-C), triglycerides, and blood pressure (BP) control on the risk of recurrent stroke or major cardiovascular events in patients with stroke is not well defined.
Methods: We randomized 4731 patients with recent stroke or transient ischemic attack and no known coronary heart disease to atorvastatin 80 mg per day or placebo.
Results: After 4.9 years, at each level of LDL-C reduction, subjects with HDL-C value above the median or systolic BP below the median had greater reductions in stroke and major cardiovascular events and those with a reduction in triglycerides above the median or diastolic BP below the median showed similar trends. There were no statistical interactions between on-treatment LDL-C, HDL-C, triglycerides, and BP values. In a further exploratory analysis, optimal control was defined as LDL-C <70 mg per deciliter, HDL-C >50 mg per deciliter, triglycerides <150 mg per deciliter, and SBP/DBP <120/80 mm Hg. The risk of stroke decreased with as the level of control increased (hazard ratio [95% confidence interval] 0.98 [0.76 to 1.27], 0.78 [0.61 to 0.99], 0.62 [0.46 to 0.84], and 0.35 [0.13 to 0.96]) for those achieving optimal control of 1, 2, 3, or 4 factors as compared to none, respectively. Results were similar for major cardiovascular events.
Conclusions: We found a cumulative effect of achieving optimal levels of LDL-C, HDL-C, triglycerides, and BP on the risk of recurrent stroke and major cardiovascular events. The protective effect of having a higher HDL-C was maintained at low levels of LDL-C.
Similar articles
-
Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.Atherosclerosis. 2009 Jun;204(2):515-20. doi: 10.1016/j.atherosclerosis.2008.09.008. Epub 2008 Sep 18. Atherosclerosis. 2009. PMID: 18962621 Clinical Trial.
-
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.Arch Neurol. 2011 Oct;68(10):1245-51. doi: 10.1001/archneurol.2011.146. Epub 2011 Jun 13. Arch Neurol. 2011. PMID: 21670382 Clinical Trial.
-
Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.Nutr Metab Cardiovasc Dis. 2002 Feb;12(1):29-35. Nutr Metab Cardiovasc Dis. 2002. PMID: 12125227
-
Atorvastatin in prevention of stroke and transient ischaemic attack.Expert Opin Pharmacother. 2007 Nov;8(16):2789-97. doi: 10.1517/14656566.8.16.2789. Expert Opin Pharmacother. 2007. PMID: 17956199 Review.
-
["Treating to New Targets": plea for a LDL cholesterol target of or below 75 mg/dl in any patient with coronary heart disease].Rev Med Liege. 2005 Apr;60(4):264-7. Rev Med Liege. 2005. PMID: 15943105 Review. French.
Cited by
-
Atorvastatin in stroke: a review of SPARCL and subgroup analysis.Vasc Health Risk Manag. 2010 Apr 15;6:229-36. doi: 10.2147/vhrm.s6795. Vasc Health Risk Manag. 2010. PMID: 20407630 Free PMC article.
-
Dyslipidaemia was correlated to the posterior circulation infarction in non-diabetic populations.Lipids Health Dis. 2018 Jun 26;17(1):150. doi: 10.1186/s12944-018-0799-0. Lipids Health Dis. 2018. PMID: 29945627 Free PMC article.
-
[Report of the 2nd NeuroUpdate from the MedUpdate series in Wiesbaden].Nervenarzt. 2010 Aug;81(8):998-1002. doi: 10.1007/s00115-010-3037-1. Nervenarzt. 2010. PMID: 20617428 German. No abstract available.
-
[Secondary prevention of stroke according to PRoFESS and SPARCL].Internist (Berl). 2009 Nov;50(11):1227-38. doi: 10.1007/s00108-009-2471-2. Internist (Berl). 2009. PMID: 19830399 German.
-
Serum lipid profiles and post-stroke depression in acute ischemic stroke patients.Neuropsychiatr Dis Treat. 2019 Jun 17;15:1573-1583. doi: 10.2147/NDT.S204791. eCollection 2019. Neuropsychiatr Dis Treat. 2019. PMID: 31354274 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical